The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Coinbase Global, Inc. | Common- Class A | 19260Q107 | 41,418,874 | 238,149 | SH | OTR | 238,149 | 0 | 0 | ||
Corvus Pharmaceuticals, Inc. | Common | 221015100 | 5,765,084 | 3,275,616 | SH | SOLE | 3,275,616 | 0 | 0 | ||
Couchbase, Inc. | Common | 22207T101 | 598,064 | 26,557 | SH | OTR | 26,557 | 0 | 0 | ||
Fusion Pharmaceuticals, Inc. | Common | 36118A100 | 28,328,444 | 2,947,809 | SH | SOLE | 2,947,809 | 0 | 0 | ||
Kanzhun Limited | ADS | 48553T106 | 1,574,777 | 94,809 | SH | OTR | 94,809 | 0 | 0 | ||
Mineralys Therapeutics, Inc. | Common | 603170101 | 19,800,029 | 2,302,329 | SH | SOLE | 2,302,329 | 0 | 0 | ||
Mirum Pharmaceuticals, Inc. | Common | 604749101 | 963,149 | 32,627 | SH | OTR | 32,627 | 0 | 0 | ||
Paylocity Holding Corporation | Common | 70438V106 | 93,702,718 | 568,412 | SH | SOLE | 568,412 | 0 | 0 | ||
Q2 Holdings, Inc. | Common | 74736L109 | 33,753,966 | 777,562 | SH | SOLE | 777,562 | 0 | 0 | ||
Quantumscape Corp | Common- Class A | 74767V109 | 224,575 | 32,313 | SH | OTR | 32,313 | 0 | 0 | ||
Rimini Street, Inc. | Common | 76674Q107 | 77,058,966 | 23,565,433 | SH | SOLE | 23,565,433 | 0 | 0 | ||
Uber Technologies, Inc. | Common | 90353T100 | 292,827 | 4,756 | SH | OTR | 4,756 | 0 | 0 | ||
UiPath, Inc. | Common- Class A | 90364P105 | 13,391,517 | 539,111 | SH | OTR | 539,111 | 0 | 0 | ||
Vacasa, Inc. | Common- Class A | 91854V107 | 7,693,445 | 938,225 | SH | SOLE | 938,225 | 0 | 0 |